Return to Listing

186 result(s) for Multiple Myeloma

PI Name Protocol # Title
Edward Neuwelt IRB00000922 Phase II Clinical Trial of Patients with High-Grade Glioma Treated with Intra-arterial Carboplatin-based Chemotherapy, Randomized to Treatment with or without Delayed Intravenous Sodium Thiosulfate as a Potential Chemoprotectant against Severe Thrombocytopenia
Edward Neuwelt IRB00001012 A Phase II Study of Patients with Newly Diagnosed Primary Central Nervous System Lymphoma Treated with Methotrexate/BBBD, and Adding Rituximab (an anti CD-20 Antibody) and Carboplatin, to the Treatment Regimen
Christopher Ryan IRB00001666 A Multicenter, Open-Label Single-Arm Study of YONDELIS (trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment
Edward Neuwelt IRB00002868 Phase I/II Study of Carboplatin, Melphalan and Etoposide Phosphate in Conjunction with Osmotic Opening of the Blood-Brain Barrier and Delayed Intravenous Sodium Thiosulfate Chemoprotection, in Previously Treated Subjects with Anaplastic Oligodendroglioma or Oligoastrocytoma
Vassiliki Tsikitis IRB00003082 Oregon Colorectal Cancer Registry
David Koeller IRB00003120 A Global, Multi-Center, Long-Term, Observational Survey of Patients with Hunter Syndrome (Mucopolysaccharidosis II) - Hunter Outcome Survey (HOS)
Brett Sheppard IRB00003609 Oregon Pancreas Tumor Registry
Shoukhrat Mitalipov IRB00003892 [STEM CELLS] Histocompatible human pluripotent cells
Fay Horak IRB00004131 Exercise, Brain Imaging, Cognition, and Gait in Parkinsonism
Edward Neuwelt IRB00005056 Phase I/II Study of Intra-arterial Melphalan Given with Intra-arterial Carboplatin, Osmotic Blood-Brain Barrier Disruption and Delayed Otoprotective Sodium Thiosulfate for Patients with Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
Kevin Billingsley IRB00005222 Oregon Liver Tumor Registry
Damien Fair IRB00005239 Typical and Atypical Brain Development
Julie Graff IRB00005254 A Phase II Study of CTLA Blockade by Ipilimumab plus Androgen Suppression Therapy in Patients with an Incomplete Response to AST Alone for Metastatic Prostate Cancer
Tomasz Beer IRB00005688 A Phase II study of MAOA inhibitor plus docetaxel in patients receiving and progressing on docetaxel therapy
Dennis Crawford IRB00006045 A Randomized Comparison of NeoCart to Microfracture for the Repair of Articular Cartilage Injuries in the Knee
Jack Kron IRB00006168 Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial
Kathleen Kemmer IRB00006256 I-SPY 2 TRIAL: Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2
Joel Nigg IRB00006258 Longitudinal Brain Imaging Study of ADHD
Chad Hagen IRB00006308 Unobtrusive measurement of sleep disordered breathing in the home
Shoukhrat Mitalipov IRB00006709 [STEM CELLS] Mitochondrial gene replacement in human oocytes
Daniel Clayburgh IRB00006918 RTOG 0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Stephen Spurgeon IRB00007195 A Phase II Proof of Concept Trial to Study Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using a Comprehensive in Vitro Kinase Inhibitor Panel to Select Individualized Targeted Therapies
Christopher Ryan IRB00007404 S0931 EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
Eric Simpson IRB00008446 Skin Barrier Function Assessment in Rare Diseases Caused by Abnormal Sterol and Isoprenoid Metabolism: A Pilot Study
Richard Maziarz IRB00008706 A Phase II Controlled Trial of a Single ProHema-CB unit (Ex Vivo CXCR4-Upregulated CD34+ Hematopoietic Progenitor Cells, Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative Conditioning For Patients Age 15-65 Years With Hematologic Malignancies
Charles Henrikson IRB00008728 Standard v. Enhanced MRI-Guided Ablation in the Treatment of Ventricular Tachycardia
Joshi Alumkal IRB00008791 The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men with Biochemically Relapsed Hormone Sensitive Prostate Cancer
William Hoffman IRB00008874 PVAMC / OHSU J: Pilot study of the dose response of entacapone on methamphetamine induced interest, mood elevation, and reward
Andy Chen IRB00008906 GO27834: A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of pinatuzumab vedotin (DCDT2980S) in Combination with Rituximab or Polatuzumab Vedotin (DCDS4501A) in Combination with Rituximab and A Non Randomized phase Ib/II Evaluation of Polatuzumab Vedotin in Combination with Obinutuzumab in Patients with Relapsed or Refractory B-cell Non- Hodgkin’s Lymphoma
Sonemany Salinthone IRB00008908 PVAMC / OHSU: Elucidating the Mechanisms that Mediate the Effects of Lipoic Acid in Multiple Sclerosis
Fay Horak IRB00008979 Frontal Cortex and Gait Freezing in Parkinson's Disease: Rehabilitation Impact
Charles Thomas IRB00009013 A Study to Determine the Immune Profile of Rectal Adenocarcinoma and its Correlation with the Efficacy of Neoadjuvant Chemoradiotherapy
Kathleen Kemmer IRB00009076 A phase III randomized, double blind, placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative AI treated, locally advanced or metastatic breast cancer who progressed on or after mTOR inhibitor based treatment
Andrew Ahmann IRB00009157 VAPORHCS / OHSU J: Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
Michael Shapiro IRB00009174 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome (Odyssey Outcomes)
Tomasz Beer IRB00009204 Radiologically Guided Biopsies of Metastatic Castration Resistant Prostate Cancer to Identify Adaptive Mechanisms of Resistance
Joshi Alumkal IRB00009259 Identifying Mechanisms of Resistance to Enzalutamide (MDV3100) Treatment in Men with Castration-Resistant Prostate Cancer
Winston Chamberlain IRB00009280 Randomized Clinical Trial of OCT-Guided Laser-Assisted Lemellar Anterior Keratoplasty in Adults for Keratoconus
Winston Chamberlain IRB00009282 Randomized Clinical Trial of OCT-Guided Laser-Assisted Lamellar Anterior Keratoplasty in Adults for Stromal Opacities
Saurabh Gupta IRB00009290 Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional MR (The COAPT Trial)
Deniz Erten-Lyons IRB00009333 A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease. BAN2401-G000-201
Charlotte Kubicky IRB00009340 Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)
Julie Graff IRB00009352 A phase 2, randomized, 3-arm study of abiraterone acetate alone, abiraterone acetate plus degarelix, a GnRH antagonist, and degarelix alone for patients with prostate cancer with a rising PSA or a rising PSA and nodal disease following definitive radical prostatectomy
Richard Maziarz IRB00009375 A Phase 1-2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells after Partially Mismatched, Related, T Cell-Depleted HSCT
Emma Scott IRB00009398 A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age
Gina Vaccaro IRB00009414 A Phase III Study of FOLFIRINOX with or without Hyperacute-Pancreas (Algenpantucel-L) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Rodney Pommier IRB00009420 Oregon Index of Endocrine Neoplasias (ORION)
Emma Scott IRB00009421 A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Kevin Winthrop IRB00009463 The Oregon nontuberculous mycobacteria (NTM) cohort; immune correlates of pulmonary NTM disease progression
Christopher Ryan IRB00009464 A Phase II Study of Sorafenib with Chemotherapy, Radiation, and Surgery for High-Risk Soft Tissue Sarcomas
Matthew Taylor IRB00009480 A Randomized, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer
Richard Maziarz IRB00009571 A Phase II, Randomized Trial of Standard of Care with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia
Richard Maziarz IRB00009585 Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT
Scott Chadderdon IRB00009594 Cardiovascular Inflammation Reduction Trial (CIRT)
Fay Horak IRB00009616 Balance Deficits in Multiple Sclerosis and Cerebellar Dysfunction
Erin Gilbert IRB00009694 The Use of Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE MRI) in the Management of Pancreatic Cancer
Garet Lahvis IRB00009747 Oregon Animation Test for Social Reciprocity (OATS)
Emma Scott IRB00009761 A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma
Michael Shapiro IRB00009813 International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA)
Lynne Shinto IRB00009880 Omega 3 PUFA for the vascular component of age-related cognitive decline
Akram Khan IRB00009885 Safety and Efficacy of A Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis IM136003
Julie Graff IRB00009892 PVAMC / OHSU J: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
Matthew Taylor IRB00009902 A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Emma Scott IRB00009936 A Multicenter, Randomized, Open-Label, Phase 2 Study of Carfilzomib With or Without ARRY-520 in Patients with Advanced Multiple Myeloma
Deniz Erten-Lyons IRB00010037 Randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with donepezil; study 1
Jeffrey Kaye IRB00010057 A Seamless Phase IIa/IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of MK-7622 as an Adjunctive Therapy for Symptomatic Treatment in Subjects with Alzheimer’s Disease. MK-7622-012
Steven Shea IRB00010101 Circadian rhythms and cardiovascular risk
Paul Spellman IRB00010163 Reconstructing the Tumor Genome in Peripheral Blood
Lucinda Hugos IRB00010164 PVAMC / OHSU J: Developing and Testing a Comprehensive MS Spasticity Management Program
Matthew Taylor IRB00010177 A Phase I, Open-Label, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of avelumab (MSB0010718C) in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Kevin Winthrop IRB00010178 The Safety and Effectiveness of the VaricElla zosteR VaccinE (VERVE) in Anti-TNF Users Trial
Donna Graville IRB00010199 The effect of age and bolus consistency on the swallowing efficiency of adults with and without dysphagia
Katharine Simmons IRB00010228 Tamoxifen for the treatment of unfavorable bleeding patterns in Etonogestrel contraceptive implant users
Joshi Alumkal IRB00010241 Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment
Neha Rich-Garg IRB00010253 PROMIS in Rheumatology
Kim-Hien Dao IRB00010262 Prospective Evaluation of ruxolitinib Efficacy for CNL/aCML Patients with Mutation of CSF3R
Deniz Erten-Lyons IRB00010264 Protocol H8A-MC-LZAZ(a)/ADC-040-A4 Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4 Study)
Kevin Winthrop IRB00010278 Evaluation of the 4th Generation QuantiFERON–TB Gold test (CST001) for the detection of tuberculosis infection
Scott Chadderdon IRB00010299 Physical Activity and Obesity: The Role of Nitric Oxide and Eicosanoids in Regulating Capillary Perfusion and Vascular Insulin Resistance
Xin Li IRB00010345 Contrast Enhanced MRI of the Prostate
Michael Shapiro IRB00010361 CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia (CASCADE FH Registry)
Stephen Heitner IRB00010369 A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (ISIS 420915-CS2 FAP)
Laura Carim Todd IRB00010373 Behavioral Interventions to Target Self-Control
Stephen Spurgeon IRB00010383 A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-Lag-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas
Akram Khan IRB00010386 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS 314d-MR Added-On to Treprostinil, Inhaled (Tyvaso®) in Subjects with Pulmonary Arterial Hypertension
Charles Henrikson IRB00010425 A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure (GENETIC-AF)
Kevin Winthrop IRB00010433 A pilot study for the Varicella Zoster Vaccine (VERVE) Trial
Tomasz Beer IRB00010479 A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
Saurabh Gupta IRB00010503 Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial (PORTICO)
Kerri Winters IRB00010504 Whole Body Vibration Training for Healthy Body Composition in Young Adults
Frederick Tibayan IRB00010527 A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiac Surgery with Cardiopulmonary Bypass (GTI-1307)
Lara Davis IRB00010529 SARC024: A blanket protocol to study oral regorafenib in patients with refractory liposarcoma, osteogenic sarcoma, and Ewing/Ewing–like sarcomas
Steven Bailey IRB00010535 Optical coherence tomography angiography in neovascular age-related macular degeneration
Michael Heinrich IRB00010537 A Phase I, Multicenter, Open-Label Study of Oral ABL001 in Patients with Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Charles Henrikson IRB00010538 Late Sodium Current Blockade in High-Risk ICD Patients - Ranolazine ICD Trial (RAID)
Charles Lopez IRB00010540 A Phase III, Multicenter, Open-Label, Randomized Study of nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma
Kimberly Mauer IRB00010548 Functional Imaging of Light-Induced Activation of Pain-Related Circuitry in Fibromyalgia as a Marker for Central Sensitization
Sancy Leachman IRB00010561 War on Melanoma: Enlisting a cohort of melanoma survivors and their families
Cailin Sibley IRB00010580 Risk for Development of ANCA in First-Degree Relatives of Patients with ANCA-Associated Vasculitis
Matthew Taylor IRB00010605 A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies
Peter Andersen IRB00010613 Phase II Randomized Trial of Transoral Surgical Resection followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Matthew Taylor IRB00010630 CLGX818X2109: The LOGIC 2 trial, A phase II, multi-center, open-label study of sequential LGX818/MEK162 combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally advanced or metastatic BRAF V600 melanoma
Stephen Heitner IRB00010645 A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy (GS-US-361-1157)
Christopher Ryan IRB00010659 A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator’s Choice in Subjects with Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy
Stephen Heitner IRB00010707 Novel Predictors of Outcome in Hypertrophic Cardiomyopathy (HCMR)
Peter Jacobs IRB00010708 Improving speech intelligibility in noise through an interactive video game
Mary Samuels IRB00010709 OCTRI Research Volunteer Registry
Rahel Nardos IRB00010729 Urinary Microbiomes: Do they play a role in Urgency Urinary Incontinence?
John Nutt IRB00010745 Effects of augmenting cholinergic function on gait and balance
Andrew Riley IRB00010750 Parent and Provider Perceptions of Behavioral Video Tutorials in Pediatric Primary Care
Matthew Brodsky IRB00010755 A Phase 3 Double-Blind, Placebo Controlled, Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects with Early Parkinson Disease
Charles Lopez IRB00010768 A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor, Ruxolitinib or Placebo in Combination with Capecitabine in Subjects with Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy
Joseph Quinn IRB00010809 A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered By Intravenous Infusion in Patients with Parkinson's Disease
Barry Oken IRB00010810 Improving sleep quality in people with insomnia
Lissi Hansen IRB00010828 Mother-Daughter Care Dyad Relationships in the Context of Hospice at Home
Kim-Hien Dao IRB00010849 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine with or without Birinapant with a Single Arm Open-Label Run-In Phase in Subjects with Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Eric Anderson IRB00010866 Safety and Efficacy of nab®-paclitaxel (Abraxane®) in Combination with Carboplatin as First Line Treatment in Elderly Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study
Michael Heinrich IRB00010886 A companion sample collection protocol to support the discovery of the mechanisms of resistance to targeted cancer therapies.
Richard Maziarz IRB00010941 A Multi-center Phase II Trial Randomizing Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls
Thomas Hwang IRB00010949 Functional Optical Coherence Tomography-Derived Biomarkers for Diabetic Retinopathy
Jeremy Cetnar IRB00011046 S1400, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Angela Senders IRB00011049 Mindfulness-based Stress Reduction for Multiple Sclerosis
Rachel Cook IRB00011076 A Phase I Dose Escalation with Two Disease Specific Expansions, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of LOR-253 in Patients with Relapsed or Refractory Hematologic Malignancies
Emma Scott IRB00011097 A Feasibility Study of Myeloablative BEAM Allogeneic Transplantation Followed by Oral Ixazomib Maintenance Therapy in Patients with Relapsed High-Risk Multiple Myeloma
Emma Scott IRB00011120 A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination with either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects with Multiple Myeloma
Daniel Herzig IRB00011161 A Phase II Multicenter Randomized Trial Evaluating 3-Year Disease-Free Survival in Patients with Locally Advanced Rectal Cancer Treated with Chemoradiation Plus Induction or Consolidation Chemotherapy, and Total Mesorectal Excision or Non-Operative Management
Wayne Clark IRB00011170 Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
Christopher Ryan IRB00011171 A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
Nicole Marshall IRB00011175 Maternal Body Composition Regulates Placental Function and Fetal Growth
Aaron Ziegler IRB00011177 Effects of neural respiratory drive on laryngeal function during physical activity
Atulya Deodhar IRB00011216 A Multicenter, Randomized, Double-Blind, Placebo-Controlled 24-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients with Active Psoriatic Arthritis
Julie Graff IRB00011227 VA/OHSU (J): A Phase I/II Trial of Concurrent Chemohormonal Therapy Using Enzalutamide (MDV-3100) and Cabazitaxel in Patients with Metastatic Castration Resistant Prostate Cancer
Kelvin MacDonald IRB00011230 A Two-Part Multicenter Prospective Longitudinal Study of CFTR-Dependent Disease Profiling in Cystic Fibrosis (PROSPECT)
Donna Graville IRB00011259 Voice Use and Vocal Effort in Older Adults
Jacqueline Vuky IRB00011260 A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Advanced/Unresectable or Metastatic Urothelial Cancer
Arthur Hung IRB00011268 Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide (MDV3100) in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy
Christopher Ryan IRB00011283 A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone (Including a Lead-In Phase IB Dose-Escalation Portion) In Patients With Advanced Or Metastatic Renal Cell Carcinoma.
Michael Shapiro IRB00011305 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients with Hypertriglyceridemia (ISIS 304801 CS16 - COMPASS)
Stephen Spurgeon IRB00011311 A Phase 1/2 Proof-of-concept study of the combination of ACP-196 and ACP-319 in subjects with B-cell malignancies
Matthew Taylor IRB00011313 A Phase II Study of Combination Treatment with HF10, a Replication-competent HSV-1 Oncolytic Virus, and Ipilimumab in Patients with Stage IIIB, Stage IIIC, or Stage IV Unresectable or Metastatic Malignant Melanoma
Diane Stadler IRB00011332 Dietary Intake and Behaviors in Adults with Autism Spectrum Disorders
Kathleen Kemmer IRB00011351 A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
William Rooney IRB00011378 Investigation of a Novel Biomarker of Cerebral Metabolic Activity in Progressive Forms of Multiple Sclerosis: Trans-Capillary Water Molecule Flux
Deniz Erten-Lyons IRB00011407 A Phase 2a Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Mark Pennesi IRB00011448 A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Retinoschisin (rAAV2tYF-CB-hRS1) in Patients with X-linked Retinoschisis
Khaled Tolba IRB00011462 A Randomized, Open-Label, Phase I Trial of Continuous, Intermittent, and Pulsatile Selumetinib (AZD6244) plus nab-Paclitaxel as Second-Line Treatment for Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
Andrew Ahmann IRB00011466 A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of LX4211 as Adjunct Therapy in Adult Patients with Type 1 Diabetes Mellitus Who have Inadequate Glycemic Control with Insulin Therapy.
Kevin Winthrop IRB00011471 A Randomized, Open-Label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacterium avium complex (MAC) that are refractory to treatment
Allison Lindauer IRB00011476 Alzheimer's Care via Telemedicine for Oregon (ACT-ON), Phase I
Sarah Feldstein Ewing IRB00011481 Motivational Interviewing and Neuroimaging with Adolescents (MINA)
Elie Traer IRB00011486 A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects with Advanced Hematologic Malignancies with an IDH2 Mutation
Lara Davis IRB00011533 SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients with Advanced Sarcomas
Henry Milczuk IRB00011538 Developing a National Registry for JORRP (Juvenile Onset Recurrent Respiratory Papillomatosis)
Eric Simpson IRB00011596 A Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Tralokinumab in Adult Subjects with Moderate-to-Severe Atopic Dermatitis
Bayard Lyons IRB00011606 Alzheimer's Comprehensive Treatment Network of Oregon and Washington (ACTNOW!)
Alexey Danilov IRB00011620 A Phase II, Open-Label Study Of Obinutuzumab Plus Bendamustine (BG) In Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Eric Simpson IRB00011632 A Phase Ii, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients with Persistent Moderate to Severe Atopic Dermatitis that is Inadequately Controlled by Topical Corticosteroids
Matthew Taylor IRB00011638 A Phase 2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects with Advanced Head and Neck Squamous Cell Carcinoma
Doria Thiele IRB00011639 Variability of Breast Milk Storage Technique and Impact on Infant Growth
David Spencer IRB00011654 An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray in Adolescents and Adults with Cluster Seizures
Jonathan Lindner IRB00011664 Assessment of Limb Perfusion with Sonazoid Contrast Ultrasound
Khaled Tolba IRB00011671 TIGER 1: A Randomized, Open-Label, Phase II Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)
Matthew Taylor IRB00011688 A Phase 1 Study of the Oral TRK Inhibitor LOXO-101 in Adult Patients with Solid Tumors
Christopher Ryan IRB00011698 A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath
Khaled Tolba IRB00011740 TIGER-3: A Phase 3, Open-label, Multicenter, Randomized Study of Oral Rociletinib (CO 1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients with Mutant EGFR Non-small Cell Lung Cancer (NSCLC) after Failure of at Least 1 Previous EGFR-directed Tyrosine Kinase Inhibitor (TKI) and Platinum-doublet Chemotherapy
Gina Vaccaro IRB00011746 I4T-MC-JVDE: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib
Jeremy Cetnar IRB00011749 Randomized Phase 2 Trial of ACP-196 and Pembrolizumab Immunotherapy Dual CHECKpoint Inhibition In Platinum Resistant Metastatic Urothelial Carcinoma (RAPID CHECK study)
Jeffrey Jensen IRB00011751 Pharmacodynamics (Suppression of Ovulation) and Pharmacokinetics Following a Single Subcutaneous Administration of Depo Provera® CI 150 mg/mL, Depo Provera® CI 300mg/2mL, or During Two Cycles of Depo-subQ Provera 104®
Kerri Winters IRB00011765 Health & Mobility in Prostate Cancer Survivors
Khaled Tolba IRB00011778 Protocol D4193C00001: A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Khaled Tolba IRB00011779 Protocol D4193C00003: A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Alison Edelman IRB00011784 Determining the impact of combined hormonal contraceptives on ulipristal acetate
Stephen Spurgeon IRB00011800 Intergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Matthew Taylor IRB00011804 A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Jeffrey Jensen IRB00011820 Evaluation of the Effectiveness, Feasibility, Safety and Tolerability of the ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception
Barry Oken IRB00011847 Meditation or Health & Wellness Education via Internet for Adults 50-80 Years Old
Victoria Holiday IRB00011875 Buspirone, in combination with amantadine, for the treatment of levodopa-induced dyskinesia
Brandon Hayes-Lattin IRB00011894 Protocol CCTL019B2206: A multicenter study of apheresis collection of peripheral blood mononuclear cells (PBMC) in patients with CD19 expressing malignancies who could be eligible for a CTL019 clinical research trial
Khaled Tolba IRB00011967 An open label, multicenter, phase 2 study to determine the safety and efficacy of BIND-014 (docetaxel nanoparticles for injectable suspension) as a second-line therapy for patients with KRAS mutation positive or Squamous cell non-small cell lung cancer
Amira Al-Uzri IRB00011992 Ensuring Accurate Weight Assessment in Newborns and Young Infants (babyTAPE)
Matthew Taylor IRB00012008 CPDR001X2101: Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients with Advanced Malignancies
Lara Davis IRB00012039 Sarcoma Survivorship Registry
Michael Heinrich IRB00012061 A Phase 1 Study of BLU-285 in Patients with Gastrointestinal Stromal Tumors (GIST) and other Relapsed and Refractory Solid Tumors
Marian Smith IRB00012075 Looking at Chronic Fatigue Syndrome through a New Lens: Establishing Objective Diagnostic Criteria for Systemic Exertion Intolerance Disease
Alexey Danilov STUDY00015069 A randomized phase III study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib alone in untreated older patients (≥ 65 years of age) with Chronic Lymphocytic Leukemia (CLL)
MinKyoung Song STUDY00015075 Healthy Parents, Healthy Families

You may also qualify for Phase 1 Program trials.

For more information:
Call: 503-494-1080